This is an archived document. The links are no longer being updated.
TB Notes 3, 2001
Surveillance data for the year 2000 were posted on
October 2, 2001, to the DTBE Web site: www.cdc.gov/nchstp/tb/
. You will find it on the DTBE Home page under “What’s New.”
Several NTCA Workgroup meetings are being held this fall. On October
18 and 19 the NTCA met with CDC staff to discuss the development
of a “hands-on” genotyping manual for TB controllers. The NTCA Information
Technology Workgroup will be meeting with CDC staff on November
6 for what is being called a TIMS summit. Also, the NTCA Contact
Investigation Workgroup will meet in Atlanta November 15-16.
Please note that a new drug called Remicade, which is labeled and
approved for use in patients with rheumatoid arthritis, is associated
with reactivation of latent TB infection. Because of this reaction,
persons receiving Remicade should first receive a tuberculin skin
test, and should not take the drug if found to have latent TB infection.
Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb
Please send comments/suggestions/requests
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333